Logo image of ADAP

ADAPTIMMUNE THERAPEUTICS-ADR (ADAP) Stock Fundamental Analysis

NASDAQ:ADAP - Nasdaq - US00653A1079 - ADR - Currency: USD

0.2423  -0.01 (-3.08%)

After market: 0.2584 +0.02 (+6.64%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADAP. ADAP was compared to 559 industry peers in the Biotechnology industry. ADAP has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ADAP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ADAP had negative earnings in the past year.
In the past year ADAP has reported a negative cash flow from operations.
In the past 5 years ADAP always reported negative net income.
ADAP had negative operating cash flow in 4 of the past 5 years.
ADAP Yearly Net Income VS EBIT VS OCF VS FCFADAP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -44.22%, ADAP is in line with its industry, outperforming 53.85% of the companies in the same industry.
Industry RankSector Rank
ROA -44.22%
ROE N/A
ROIC N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ADAP Yearly ROA, ROE, ROICADAP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

Looking at the Gross Margin, with a value of 99.07%, ADAP belongs to the top of the industry, outperforming 98.75% of the companies in the same industry.
ADAP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 99.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADAP Yearly Profit, Operating, Gross MarginsADAP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

ADAP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADAP has been increased compared to 1 year ago.
The number of shares outstanding for ADAP has been increased compared to 5 years ago.
The debt/assets ratio for ADAP is higher compared to a year ago.
ADAP Yearly Shares OutstandingADAP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ADAP Yearly Total Debt VS Total AssetsADAP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ADAP has an Altman-Z score of -9.36. This is a bad value and indicates that ADAP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.36, ADAP is doing worse than 71.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.36
ROIC/WACCN/A
WACC9.17%
ADAP Yearly LT Debt VS Equity VS FCFADAP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ADAP has a Current Ratio of 2.02. This indicates that ADAP is financially healthy and has no problem in meeting its short term obligations.
ADAP has a Current ratio of 2.02. This is in the lower half of the industry: ADAP underperforms 75.49% of its industry peers.
A Quick Ratio of 1.79 indicates that ADAP should not have too much problems paying its short term obligations.
ADAP has a Quick ratio of 1.79. This is in the lower half of the industry: ADAP underperforms 77.28% of its industry peers.
Industry RankSector Rank
Current Ratio 2.02
Quick Ratio 1.79
ADAP Yearly Current Assets VS Current LiabilitesADAP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 76.47% over the past year.
ADAP shows a strong growth in Revenue. In the last year, the Revenue has grown by 878.48%.
The Revenue has been growing by 175.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)76.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
Revenue 1Y (TTM)878.48%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%28.3%

3.2 Future

ADAP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 38.30% yearly.
The Revenue is expected to grow by 9.16% on average over the next years. This is quite good.
EPS Next Y-30.05%
EPS Next 2Y8.78%
EPS Next 3Y11.14%
EPS Next 5Y38.3%
Revenue Next Year-72.3%
Revenue Next 2Y-38.74%
Revenue Next 3Y-12.08%
Revenue Next 5Y9.16%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ADAP Yearly Revenue VS EstimatesADAP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
ADAP Yearly EPS VS EstimatesADAP Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADAP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADAP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADAP Price Earnings VS Forward Price EarningsADAP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADAP Per share dataADAP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.78%
EPS Next 3Y11.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ADAP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIMMUNE THERAPEUTICS-ADR

NASDAQ:ADAP (6/13/2025, 8:00:00 PM)

After market: 0.2584 +0.02 (+6.64%)

0.2423

-0.01 (-3.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners49.87%
Inst Owner Change-6.64%
Ins Owners0.21%
Ins Owner Change-0.16%
Market Cap64.22M
Analysts75.71
Price Target1.61 (564.47%)
Short Float %13.29%
Short Ratio3.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.97%
Min EPS beat(2)-75.07%
Max EPS beat(2)-24.87%
EPS beat(4)2
Avg EPS beat(4)105.18%
Min EPS beat(4)-75.07%
Max EPS beat(4)428.3%
EPS beat(8)2
Avg EPS beat(8)11.68%
EPS beat(12)5
Avg EPS beat(12)18.09%
EPS beat(16)6
Avg EPS beat(16)-5.76%
Revenue beat(2)1
Avg Revenue beat(2)-13.34%
Min Revenue beat(2)-42.36%
Max Revenue beat(2)15.67%
Revenue beat(4)3
Avg Revenue beat(4)102.41%
Min Revenue beat(4)-42.36%
Max Revenue beat(4)258.91%
Revenue beat(8)3
Avg Revenue beat(8)24.8%
Revenue beat(12)6
Avg Revenue beat(12)105.48%
Revenue beat(16)8
Avg Revenue beat(16)80.24%
PT rev (1m)-7.62%
PT rev (3m)-30.46%
EPS NQ rev (1m)-9.14%
EPS NQ rev (3m)17.14%
EPS NY rev (1m)13.48%
EPS NY rev (3m)34.29%
Revenue NQ rev (1m)18.81%
Revenue NQ rev (3m)48.51%
Revenue NY rev (1m)28.38%
Revenue NY rev (3m)27.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.36
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.16
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.68
BVpS-0.14
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 99.07%
FCFM N/A
ROA(3y)-39.8%
ROA(5y)-36.38%
ROE(3y)-362.62%
ROE(5y)-240.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.14
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.82%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.02
Quick Ratio 1.79
Altman-Z -9.36
F-Score3
WACC9.17%
ROIC/WACCN/A
Cap/Depr(3y)187.66%
Cap/Depr(5y)146.98%
Cap/Sales(3y)39.72%
Cap/Sales(5y)67.08%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
EPS Next Y-30.05%
EPS Next 2Y8.78%
EPS Next 3Y11.14%
EPS Next 5Y38.3%
Revenue 1Y (TTM)878.48%
Revenue growth 3Y207.05%
Revenue growth 5Y175.59%
Sales Q2Q%28.3%
Revenue Next Year-72.3%
Revenue Next 2Y-38.74%
Revenue Next 3Y-12.08%
Revenue Next 5Y9.16%
EBIT growth 1Y74.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-99.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.48%
OCF growth 3YN/A
OCF growth 5YN/A